Kobayashi Ken 4
4 · Pyxis Oncology, Inc. · Filed Dec 29, 2023
Insider Transaction Report
Form 4
Kobayashi Ken
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-12-29+443,514→ 443,514 totalExercise: $1.80Exp: 2033-12-29→ Common Stock (443,514 underlying) - Award
Stock Option (Right to Buy)
2023-12-29+110,878→ 110,878 totalExercise: $1.80Exp: 2033-12-29→ Common Stock (110,878 underlying)
Footnotes (2)
- [F1]The shares subject to this option will vest over four years, with 25% vesting on November 27, 2024 and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates.
- [F2]The shares subject to this option will vest upon the achievement of certain clinical milestones related to data disclosure for PYX-201.